SYT-510
| Clinical data | |
|---|---|
| Other names | SYT510 |
| Routes of administration | Oral[1] |
| Drug class | Selective endocannabinoid reuptake inhibitor (SERI)[2] |
SYT-510 is a selective endocannabinoid reuptake inhibitor (SERI) which is under development for the treatment of psychiatric disorders, anxiety disorders, mood disorders, and traumatic stress disorders.[2][1][3][4][5] It is currently being developed by a pharmaceutical company called Synendos Therapeutics.[2][1][3][4]
SERIs have been shown to both mildly and selectively increase levels of endocannabinoids such as anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) via inhibition of a newly identified biological target.[2][3][5] In September 2025, Synendos reported the successful completion of Phase 1 clinical trials in healthy volunteers, paving the way for the start of Phase 2a clinical study in Generalized Anxiety Disorder (GAD).[1][3][4][5][6]
See also
References
- ^ a b c d "Delving into the Latest Updates on SYT-510 with Synapse". Synapse. 4 August 2024. Retrieved 15 August 2024.
- ^ a b c d "SYT 510". AdisInsight. 22 January 2024. Retrieved 15 August 2024.
- ^ a b c d Kuntz, Leah (24 September 2025). "SYT-510: First-in-Class Inhibitor Targets Endocannabinoid System to Improve Mental Health Outcomes". Psychiatric Times. Retrieved 26 April 2026.
- ^ a b c Gertsch J, Chicca A (July 2024). "CNS Drug Discovery in Academia: Where Basic Research Meets Innovation". ChemBioChem e202400397. doi:10.1002/cbic.202400397. PMID 38958639.
Five years after incorporation, Synendos Therapeutics has completed non-clinical development of the [selective endocannabinoid reuptake inhibitor (SERI)] drug candidate SYT-510 and has initiated Phase 1 clinical development in healthy volunteers, marking the significant transition into a clinical stage biotech company. The mission of Synendos is to develop breakthrough safe and effective therapies for neurological and neuropsychiatric disorders through modulation of the [endocannabinoid system (ECS)] with SERIs to enable restoration of the natural functioning of the brain.
- ^ a b c Synendos Therapeutics, AG (18 January 2024). "Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510". PR Newswire. Retrieved 15 August 2024.
- ^ Synendos Therapeutics, AG (2026-05-20). "Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder". GlobeNewswire News Room. Retrieved 2026-06-18.